Author:
Zheng Nan,Zhong Jinyan,Chen Xi,Su Jia,Liu Chengjiang,Jiang Longfu
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Reference39 articles.
1. World Health Organization. Cardiovascular diseases (CVDs): key facts. 2017. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
3. Schunkert H, Boening A, von Scheidt M, Lanig C, Gusmini F, de-Waha A, et al. Randomized trial of ticagrelor vs aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J. 2019;40(29):2432–40.
4. Scott LJ. Rivaroxaban: A review for secondary CV prevention in CAD and PAD. Drugs. 2020;80(14):1465–75.
5. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–9.